Ali ebn-e Abitaleb Hospital, Children and Adolescents Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Ann Hematol. 2014 Apr;93(4):693-7. doi: 10.1007/s00277-013-1918-7. Epub 2013 Oct 23.
Intracranial hemorrhage (ICH) is one of the most severe and life-threatening manifestations occurring in the patients with factor XIII (F XIII) deficiency. The aim of this study was to describe the ICH pattern in the patients suffering from F XIII deficiency. In this case series, we investigated 38 patients with severe F XIII deficiency in south of Iran from January to May 2012. ICH pattern, neurologic complications, efficacy of treatment, and incidence of recurrence were reported. The site of ICH was intraparenchymal in 35 patients (92.1 %), subdural in 2 patients (5.2 %), and epidural hemorrhage in 1 patient (2.6 %). Besides, neurologic complications occurred in 21 patients (55.2 %), including locomotor disability in 8, psychological impairment in 7, mental disorders in 5, speech impairment in 4, and visual impairment in 2. Prophylaxis was started with a dose of 10 IU/kg Fibrogammin every 4-6 weeks for all the patients, except for one. All the patients on prophylaxis showed good response without any episodes of recurrence, except for one. The most frequent site of ICH in our patients was intraparenchymal. It seems that long-term prophylactic treatment with a dose of 10 IU/kg Fibrogammin could be effective in the prevention of CNS bleeding in the patients with F XIII deficiency. Moreover, all the patients with severe F XIII deficiency even without severe bleeding symptoms are recommended to undergo prophylactic treatment.
颅内出血 (ICH) 是因子 XIII (F XIII) 缺乏症患者中最严重和最具威胁生命的表现之一。本研究旨在描述 F XIII 缺乏症患者的 ICH 模式。在本病例系列研究中,我们调查了 2012 年 1 月至 5 月伊朗南部的 38 名严重 F XIII 缺乏症患者。报告了 ICH 模式、神经并发症、治疗效果和复发发生率。35 名患者(92.1%)的 ICH 部位为脑实质内,2 名患者(5.2%)为硬膜下血肿,1 名患者(2.6%)为硬膜外血肿。此外,21 名患者(55.2%)出现神经并发症,包括 8 名运动障碍、7 名心理损害、5 名精神障碍、4 名言语障碍和 2 名视力障碍。除 1 名患者外,所有患者均开始每 4-6 周给予 10IU/kg Fibrogammin 进行预防治疗。所有接受预防治疗的患者均反应良好,无复发。我们患者中 ICH 最常见的部位是脑实质内。似乎每 4-6 周给予 10IU/kg Fibrogammin 的长期预防治疗可能对预防 F XIII 缺乏症患者的中枢神经系统出血有效。此外,所有严重 F XIII 缺乏症患者,即使没有严重出血症状,也建议进行预防治疗。